A lot of studies suggested that indicating addition of local therapy showed prolonged survival benefit than EGFR-TKI alone in EGFR-mutant NSCLC patients with oligoprogressive disease, including intracranial metastases, primary lesion progression, and liver metastasis (31–34). This evidence concerns the gene EGFR and non-small cell lung carcinoma.